Adipocytokines, inflammatory and oxidative stress markers of clinical relevance altered in young overweight/obese subjects

Clinical Biochemistry

Volumn 49, Issue 7-8, 2016, Pages 548-553

  Ottobelli Chielle, Eduardo ^a,c   de Souza, Willian Marciel ^c   da Silva, Thainan Paz ^a   Moresco, Rafael Noal ^a,b   Moretto, Maria Beatriz ^a,b  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b Center of Healthy Sciences   (Brazil)

^c UNIVERSIDADE DO OESTE DE SANTA CATARINA   (Brazil)

Author keywords

Adenosine deaminase; Adipocytokines; Dipeptidyl peptidase IV; Obesity; Young adult

Indexed keywords

ADENOSINE DEAMINASE; ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; MALONALDEHYDE; RESISTIN; RETINOL BINDING PROTEIN 4; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL GROUP; ADA PROTEIN, HUMAN; ADIPOQ PROTEIN, HUMAN; AUTACOID; DPP4 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL; INTERLEUKIN 6; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, HUMAN; RETN PROTEIN, HUMAN;

ADULT; ANTHROPOMETRY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIET RESTRICTION; ENZYME ACTIVITY; FEMALE; FERRIC REDUCING ANTIOXIDANT POWER; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MALE; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; YOUNG ADULT; ADOLESCENT; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; GLUCOSE BLOOD LEVEL; IMMUNOASSAY; INSULIN RESISTANCE; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS;

ADENOSINE DEAMINASE; ADIPONECTIN; ADOLESCENT; ADULT; BIOMARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIPEPTIDYL PEPTIDASE 4; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOASSAY; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; OBESITY; OVERWEIGHT; OXIDATIVE STRESS; PROGNOSIS; RESISTIN; RETINOL-BINDING PROTEINS, PLASMA; YOUNG ADULT;

EID: 84956893311     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2016.01.003     Document Type: Article

References (46)

1. World Health Organization Obesity: preventing and managing the global epidemic - report of a WHO consultation. World Health Organ Tech Rep Ser 2000, 894. (i-xii, 1-253 [01/07/15]).
2. Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância de Doenças e Agravos não Transmissíveis e Promoção da Saúde VIGITEL Brasil 2014. Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. Brasília-DF 2015, (http://bvsms.saude.gov.br/bvs/publicacoes/vigitel_brasil_2014.pdf [09/07/15]).
3. Marie N.G., Fleming T., Robinson M., Thomson B., Graetz N., Margono C., Mullany E.C., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, S0140-6736(14):60460-60468. (Early Online Publication).
4. Park K.H., Zaichenko L., Brinkoetter M., Thakkar B., Sahin-Efe A., Joung K.E., et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J. Clin. Endocrinol. Metab. 2013, 98:4899-4907.
5. Juge-Aubry C.E., Henrichot E., Meier C.A. Adipose tissue: a regulator of inflammation. Best Pract. Res. Clin. Endocrinol. Metab. 2005, 19:547-566.
6. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., Tataranni P.A. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001, 86:1930-1935.
7. Deng G., Long Y., Yu Y.R., Li M.R. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS pathway. Int. J. Obes. 2010, 34:165-171.
8. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409(6818):307-312.
9. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939.
10. Blaner W.S. Retinol-binding protein: the serum transport protein for vitamin a. Endocr. Rev. 1989, 10:308-316.
11. Norseen J., Hosooka T., Hammarstedt A., Yore M.M., Kant S., Aryal P., et al. Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol independent mechanism. Mol. Cell. Biol. 2012, 32:2010-2019.
12. Tschoner A., Sturm W., Engl J., Kaser S., Laimer M., Laimer E., et al. Retinol-binding protein 4, visceral fat, and the metabolic syndrome: effects of weight loss. Obesity (Silver Spring) 2008, 16:2439-2444.
13. Kotnik P., Fischer-Posovszky P., Wabitsch M. RBP4-a controversial adipokine. Eur. J. Endocrinol. 2011, 165:703-711.
14. Fontana L., Eagon J.C., Trujillo M.E., Scherer P.E., Klein S., et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56:1010-1013.
15. Chielle E.O., Bonfanti G., De Bona K.S., Moresco R.N., Moretto M.B. Adenosine deaminase, dipeptidyl peptidase-IV activities and lipid peroxidation are increased in the saliva of obese young adult. Clin. Chem. Lab. Med. 2015 Jun, 53(7):1041-1047.
16. Yu D.M., Slaitini L., Gysbers V., Riekhoff A.G., Kähne T., Knott H.M., et al. Soluble CD26/dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Scand. J. Immunol. 2011; Feb, 73(2):102-111.
17. Lourie J.A., Weiner J.S. Practical Human Biology 1981, Academic Press, London.
18. James P.T., Leach R., Kalamara E., Shayeghi M. The worldwide obesity epidemic. Obes. Res. 2001, 12:S228-S233.
19. Gallagher D1., Heymsfield S.B., Heo M., Jebb S.A., Murgatroyd P.R., Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am. J. Clin. Nutr. 2000, 12(3):694-701.
20. Ashwell M., Hsieh S.D. Six reasons why the waist-to-height ratio is a rapid and effective global indicator for health risks of obesity and how its use could simplify the international public health message on obesity. Int. J. Food Sci. Nutr. 2005, 12(5):303-307.
21. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
22. Nagatsu T., Hino M., Fuyamada H., Hayakawa T., Sakakibara S. New chromogenic substrates for Xprolyldipeptidyl-aminopeptidase. Anal. Biochem. 1976, 74:466-476.
23. Lapenna D., Ciofani G., Pierdomenico S.D., Giamberardino M.A., Cuccurullo F. Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Radic. Biol. Med. 2001, 31:331-335.
24. Boyne A.F., Ellman G. L. A methodology for analysis of tissue sulfhydryl components. Anal. Biochem. 1972, 46:639-653.
25. Singh N., Bhardwaj P., Pandey R.M., Saraya A. Oxidative stress and Antioxidant capacity in patients with chronic pancreatitis with and without diabetes mellitus. Indian J. Gastroenterol. 2012; Sep, 31(5):226-231.
26. Asterholm I.W., Scherer P.E. Enhanced metabolic flexibility associated with elevated adiponectin levels. Am. J. Pathol. 2010, 176:1364-1376.
27. ORourke R.W., Metcalf M.D., White A.E., Madala A., Winters B.R., Maizlin I.I., et al. Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissue. Int. J. Obes. 2009, 33(9):978-990.
28. Osborn O., Olefsky J.M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 2012, 18(3):363-374.
29. Ort T., Arjona A.A., MacDougall J.R., Nelson P.J., Rothenberg M.E., Wu F. Recombinant human FIZZ3/resistin stimulates lipolysis in cultured human adipocytes, mouse adipose explants, and normal mice. Endocrinology 2005, 146:2200-2209.
30. Kok B.P., Brindley D.N. Myocardial fatty acid metabolism and lipotoxicity in the setting of insulin resistance. Heart Fail. Clin. 2012, 8:643-661.
31. Melone M., Wilsie L., Palyha O., Strack A., Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proproteinconvertasesubtilisin/kexin type 9. J. Am. Coll. Cardiol. 2012; May 8, 59(19):1697-1705.
32. Xia M., Liu Y., Guo H., Wang D., Wang Y., Ling W. Retinol binding protein 4 stimulates hepatic sterol regulatory element-binding protein 1 and increases lipogenesis through the peroxisome proliferator-activated receptor-γcoactivator 1β-dependent pathway. Hepatology 2013, 58:564-575.
33. Scribner K.B., Odom D.P., McGrane M.M. Nuclear receptor binding to the retinoic acid response elements of the phosphoenolpyruvatecarboxykinase gene in vivo: effects of vitamin A deficiency. J. Nutr. Biochem. 2006, 206-214. (18 pp.).
34. Graham T.E., Yang Q., Bluher M., Hammarstedt A., Ciaraldi T.P., Henry R.R., et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 2006, 354:2552-2563.
35. Balagopal P., Graham T.E., Kahn B.B., Altomare A., Funanage V., George D. Reduction of elevated serum retinol binding protein (RBP4) in obese children by lifestyle intervention: association with sub-clinical inflammation. J. Clin. Endocrinol. Metab. 2007, 2006-712.
36. Jones S.A., Horiuchi S., Topley N., Yamamoto N., Fuller G.M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 2001, 15:43-58.
37. Senn J.J., Klover P.J., Nowak I.A., Mooney R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002, 51:3391-3399.
38. Tsigos C., Papanicolaou D.A., Kyrou I., Defensor R., Mitsiadis C.S., Chrousos G.P. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J. Clin. Endocrinol. Metab. 1997, 82:4167-4170.
39. Boden G., Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and betacell dysfunction. Eur. J. Clin. Investig. 2002, 3:14-23.
40. Petersen E.W., Carey A.L., Sacchetti M., Steinberg G.R., Macaulay S.L., Febbraio M.A., Pedersen B.K. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E155-E162.
41. Fasshauer M., Kralisch S., Klier M., Lossner U., Bluher M., Klein J., et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocyte. Biochem. Biophys. Res. Commun. 2001, 301:1045-1050.
42. Grundy S.M. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2005, 109:433-438.
43. Grattagliano I., Palmieri V.O., Portincasa P., Moschetta A., Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hyopothesis. J. Nutr. Biochem. 2008, 19:491-504.
44. Yeum K.J., Russel R.M., Krinky N.I., Aldini G. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch. Biochem. Biophys. 2004, 430(1):97-103.
45. Frühbeck G., Gómez-Ambrosi J., Salvador J. Leptin induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes. FASEB J. 2001; Feb, 15(2):333-340.
46. Bellé L.P., Bitencourt P.E., De Bona K.S., Moresco R.N., Moretto M.B. Association between HbA1c and dipeptidyl peptidase IV activity in type 2 diabetes mellitus. Letter to the Editor. Clin. Chim. Acta 2012, 413:1020-1021.